JPWO2022026902A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022026902A5 JPWO2022026902A5 JP2023506330A JP2023506330A JPWO2022026902A5 JP WO2022026902 A5 JPWO2022026902 A5 JP WO2022026902A5 JP 2023506330 A JP2023506330 A JP 2023506330A JP 2023506330 A JP2023506330 A JP 2023506330A JP WO2022026902 A5 JPWO2022026902 A5 JP WO2022026902A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- igf
- chimeric protein
- variant
- mutations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063058888P | 2020-07-30 | 2020-07-30 | |
| US63/058,888 | 2020-07-30 | ||
| PCT/US2021/044019 WO2022026902A2 (en) | 2020-07-30 | 2021-07-30 | Chimeric proteins and methods of use for treatment of central nervous system disorders |
| US17/390,206 US20220031812A1 (en) | 2020-07-30 | 2021-07-30 | Chimeric Proteins and Methods of Use for Treatment of Central Nervous System Disorders |
| US17/390,206 | 2021-07-30 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023537318A JP2023537318A (ja) | 2023-08-31 |
| JPWO2022026902A5 true JPWO2022026902A5 (https=) | 2024-08-05 |
| JP2023537318A5 JP2023537318A5 (https=) | 2024-08-05 |
Family
ID=80002512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023506330A Pending JP2023537318A (ja) | 2020-07-30 | 2021-07-30 | 中枢神経系障害の処置のためのキメラタンパク質および使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20220031812A1 (https=) |
| EP (1) | EP4188410B1 (https=) |
| JP (1) | JP2023537318A (https=) |
| CN (1) | CN116917482A (https=) |
| AU (1) | AU2021319203A1 (https=) |
| CA (1) | CA3187734A1 (https=) |
| ES (1) | ES3061325T3 (https=) |
| WO (1) | WO2022026902A2 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023512423A (ja) | 2019-12-24 | 2023-03-27 | ジュベナ・セラピューティクス・インコーポレイテッド | 再生性ポリペプチドおよびその使用 |
| KR20240029031A (ko) | 2021-06-21 | 2024-03-05 | 쥬베나 테라퓨틱스, 인크. | 재생 폴리펩티드 및 이의 용도 |
| WO2023159067A2 (en) * | 2022-02-15 | 2023-08-24 | Silver Creek Pharmaceuticals, Inc. | Chimeric proteins for treatment of acute radiation syndrome |
| EP4658295A2 (en) * | 2023-02-02 | 2025-12-10 | Silver Creek Pharmaceuticals, Inc. | Methods of treatment using igf-1 chimeric proteins |
| CN116549667B (zh) * | 2023-05-29 | 2024-02-09 | 四川普锐特药业有限公司 | 一种pas修饰的脂质纳米粒、包含其的药物制剂，及其制备方法和用途 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| JP5577098B2 (ja) * | 2006-12-21 | 2014-08-20 | アムジエン・インコーポレーテツド | ポリペプチドを含有する安定な緩衝化された製剤 |
| ATE502114T1 (de) | 2007-06-21 | 2011-04-15 | Univ Muenchen Tech | Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität |
| CN105524176B (zh) * | 2010-05-21 | 2021-03-19 | 银溪制药股份有限公司 | 双特异性融合蛋白 |
| BR112012029611A2 (pt) | 2010-05-21 | 2017-07-25 | Merrimack Pharmaceuticals Inc | proteína de fusão biespecífica, composição farmacêutica, método de tratamento de dano ao tecido em um indivíduo, método de promoção da regeração ou sobrevivência do tecido em um indivíduo e molécula de ácido nucleico |
| DK2699598T3 (en) * | 2011-04-19 | 2019-04-23 | Pfizer | COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER |
| CN115960249A (zh) | 2015-10-02 | 2023-04-14 | 银溪制药股份有限公司 | 用于组织修复的双特异性治疗性蛋白质 |
-
2021
- 2021-07-30 JP JP2023506330A patent/JP2023537318A/ja active Pending
- 2021-07-30 WO PCT/US2021/044019 patent/WO2022026902A2/en not_active Ceased
- 2021-07-30 ES ES21849618T patent/ES3061325T3/es active Active
- 2021-07-30 US US17/390,206 patent/US20220031812A1/en not_active Abandoned
- 2021-07-30 EP EP21849618.0A patent/EP4188410B1/en active Active
- 2021-07-30 CN CN202180067368.8A patent/CN116917482A/zh active Pending
- 2021-07-30 AU AU2021319203A patent/AU2021319203A1/en active Pending
- 2021-07-30 CA CA3187734A patent/CA3187734A1/en active Pending
-
2025
- 2025-09-08 US US19/321,375 patent/US20260041738A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010518079A5 (https=) | ||
| EP0592564B1 (en) | Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology | |
| JP2010518006A5 (https=) | ||
| EP2686431B1 (en) | Antagonists of the interleukin- 1 receptor | |
| AU4238493A (en) | IGF-1 analogs | |
| JP2010513405A (ja) | 二量体プロラクチンレセプターリガンド | |
| TW200526780A (en) | TNF antagonists and TNF inhibitors comprising the same as the active ingredient | |
| JP7830450B2 (ja) | 修飾されたｉｌ－２分子及びその用途 | |
| JPWO2022026902A5 (https=) | ||
| JP2017503022A (ja) | インビボで細胞に活性型テロメラーゼを提供する組成物および方法 | |
| US7619066B2 (en) | IL-1ra variants | |
| JP5111716B2 (ja) | Ｉｇｆの構造的アナログを投与することによる中枢神経系の治療方法 | |
| JP6782932B2 (ja) | Ｎｐｒ−ａアゴニストの新規用途 | |
| JPH10147597A (ja) | 可溶性ポリペプチド | |
| CA2516458C (en) | Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis | |
| WO2023143464A1 (en) | Fusion protein and application thereof | |
| JP2021518392A5 (https=) | ||
| KR102900540B1 (ko) | 디프테리아 독소-인간 인터루킨-3 접합체를 다른 제제와 조합하여 사용해서 골수증식성 신생물을 치료하는 조합 치료 방법 | |
| EP3787661B1 (en) | Combination of temozolomide and a par-1 conjugate for treating glioblastoma | |
| AU2022367394B2 (en) | Engineered tgf-beta monomers and methods of use | |
| CA2201841A1 (en) | Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients | |
| US20240245756A1 (en) | Chimeric proteins and methods of use for treatment of neurodegenerative disorders | |
| WO2005021572A1 (ja) | Ｐｔｐ1ｂアンチセンス化合物 | |
| RU2785401C2 (ru) | Направленная регенерация переломанной кости посредством стимуляции рецептора паратиреоидного гормона | |
| TW202602916A (zh) | 用於治療自體免疫性疾病的化合物及其應用 |